Vivoryon Therapeutics AG (GB:0R3M) has released an update.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Vivoryon Therapeutics has announced promising results from its Phase 2b study of varoglutamstat, showing significant improvement in kidney function, particularly among diabetic patients. The drug demonstrated an excellent safety profile and may offer a new treatment approach for diabetic kidney disease and other kidney disorders. The company plans further studies to confirm these effects.
For further insights into GB:0R3M stock, check out TipRanks’ Stock Analysis page.